23andMe Holding Co. (ME) NASDAQ

$2.75 0.19 (7.42%)

Market Cap: $734.05M

As of 02/02/23 04:00 PM EST. Market closed.

(ME)

23andMe Holding Co. (ME) NASDAQ

$2.75 0.19 (7.42%)

Market Cap: $734.05M

As of 02/02/23 04:00 PM EST. Market closed.

23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest ... read more

23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
768
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$2.66
Previous Close
$2.56
Days Range
$2.63 - $2.79
52 week range
$2.02 - $6.31
Volume
3,315,365
Avg. Volume (30 days)
2,066,613
Market Cap
$734.05M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
286,738,037
Open
$2.66
Previous Close
$2.56
Days Range
$2.63 - $2.79
52 week range
$2.02 - $6.31
Volume
3,315,365
Avg. Volume (30 days)
2,066,613
Market Cap
$734.05M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
286,738,037

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR 23ANDME HOLDING CO
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
HIBBS KATHY L Chief Administrative Officer Dec 05, 2022 Sale $3.25 26,259 85,342 235,829 Dec 06, 2022, 05:44 PM
Selsavage Joseph Anthony Interim CFO Nov 20, 2022 Option Exercise $2.99 10,105 30,214 277,278 Nov 22, 2022, 04:14 PM
HIBBS KATHY L Chief Administrative Officer Nov 20, 2022 Option Exercise $2.99 4,628 13,838 262,088 Nov 22, 2022, 04:12 PM
Hillan Kenneth J. Chief Therapeutics Officer Nov 20, 2022 Option Exercise $2.99 4,628 13,838 197,162 Nov 22, 2022, 04:11 PM
SCHELLER RICHARD H Director Nov 11, 2022 Sale $3.24 18,421 59,684 72,388 Nov 14, 2022, 04:38 PM
BOTHA ROELOF Director Sep 06, 2022 Option Exercise $3.08 3,251 10,013 110,561 Sep 08, 2022, 04:46 PM
Chung Patrick S Director Sep 06, 2022 Option Exercise $3.08 3,414 10,515 113,034 Sep 08, 2022, 04:45 PM
Hernandez Sandra R MD Director Sep 06, 2022 Option Exercise $3.08 3,251 10,013 143,186 Sep 08, 2022, 04:42 PM
MONTGOMERY RICE VALERIE MD Director Sep 06, 2022 Option Exercise $3.08 3,577 11,017 149,049 Sep 08, 2022, 04:41 PM
Hernandez Sandra R MD Director Aug 25, 2022 Option Exercise $3.03 13,201 39,999 125,302 Aug 29, 2022, 04:33 PM
MONTGOMERY RICE VALERIE MD Director Aug 25, 2022 Option Exercise $3.03 17,821 53,998 130,839 Aug 29, 2022, 04:32 PM
Chung Patrick S Director Aug 25, 2022 Option Exercise $3.03 18,811 56,997 94,987 Aug 29, 2022, 04:31 PM
BOTHA ROELOF Director Aug 25, 2022 Option Exercise $3.03 16,501 49,998 92,677 Aug 29, 2022, 04:30 PM
Hillan Kenneth J. Chief Therapeutics Officer Aug 24, 2022 Sale $3.64 8,753 31,861 196,083 Aug 25, 2022, 05:00 PM
Schoch Steven J Chief Financial Officer Aug 20, 2022 Option Exercise $3.33 4,782 15,924 211,663 Aug 22, 2022, 06:12 PM
Hillan Kenneth J. Chief Therapeutics Officer Aug 20, 2022 Option Exercise $3.33 4,628 15,411 204,836 Aug 22, 2022, 06:12 PM
HIBBS KATHY L Chief Administrative Officer Aug 20, 2022 Option Exercise $3.33 4,628 15,411 263,636 Aug 22, 2022, 06:11 PM
Schoch Steven J Chief Financial Officer Jun 01, 2022 Option Exercise $2.82 4,782 13,485 216,445 Jun 02, 2022, 04:28 PM
Hillan Kenneth J. Chief Therapeutics Officer Jun 01, 2022 Option Exercise $2.82 4,627 13,048 209,464 Jun 02, 2022, 04:26 PM
HIBBS KATHY L Chief Administrative Officer Jun 01, 2022 Option Exercise $2.82 4,627 13,048 268,264 Jun 02, 2022, 04:25 PM
Lovell Evan Director Mar 10, 2022 Buy $4.41 11,467 50,558 11,467 Mar 11, 2022, 04:05 PM
HIBBS KATHY L Chief Legal Officer Jan 06, 2022 Option Exercise $0.42 58,800 24,696 58,800 Jan 07, 2022, 04:11 PM
Lemon Steven Vice President, Engineering Jan 05, 2022 Option Exercise $0.23 127,647 29,359 127,647 Jan 07, 2022, 04:08 PM
BROWN DOUGLAS R Director Oct 06, 2020 Buy $10.00 100,000 1,000,000 100,000 Oct 08, 2020, 08:22 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
HIBBS KATHY L Chief Administrative Officer 12/05/2022 85,342
Selsavage Joseph Anthony Interim CFO 11/20/2022 30,214
HIBBS KATHY L Chief Administrative Officer 11/20/2022 13,838
Hillan Kenneth J. Chief Therapeutics Officer 11/20/2022 13,838
SCHELLER RICHARD H Director 11/11/2022 59,684
BOTHA ROELOF Director 09/06/2022 10,013
Chung Patrick S Director 09/06/2022 10,515
Hernandez Sandra R MD Director 09/06/2022 10,013
MONTGOMERY RICE VALERIE MD Director 09/06/2022 11,017
Hernandez Sandra R MD Director 08/25/2022 39,999
MONTGOMERY RICE VALERIE MD Director 08/25/2022 53,998
Chung Patrick S Director 08/25/2022 56,997
BOTHA ROELOF Director 08/25/2022 49,998
Hillan Kenneth J. Chief Therapeutics Officer 08/24/2022 31,861
Schoch Steven J Chief Financial Officer 08/20/2022 15,924
Hillan Kenneth J. Chief Therapeutics Officer 08/20/2022 15,411
HIBBS KATHY L Chief Administrative Officer 08/20/2022 15,411
Schoch Steven J Chief Financial Officer 06/01/2022 13,485
Hillan Kenneth J. Chief Therapeutics Officer 06/01/2022 13,048
HIBBS KATHY L Chief Administrative Officer 06/01/2022 13,048
Lovell Evan Director 03/10/2022 50,558
HIBBS KATHY L Chief Legal Officer 01/06/2022 24,696
Lemon Steven Vice President, Engineering 01/05/2022 29,359
BROWN DOUGLAS R Director 10/06/2020 1,000,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2022
03/31/2022
23.98%
2Q
09/30/2022
12/31/2021
34.00%
3Q

Period of Report: 09/30/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2022
23.98%
2Q
12/31/2021
34.00%
3Q